FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1949806853> ?p ?o ?g. }

• W1949806853 endingPage "2658" @default.
• W1949806853 startingPage "2652" @default.
• W1949806853 abstract "PURPOSE To evaluate in a randomized trial the impact of three versus six cycles of cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) chemotherapy in favorable-prognosis and CVPP versus doxorubicin, vincristine, prednisone, and etoposide (AOPE) plus involved-field radiotherapy (RT) in intermediate-prognosis previously untreated Hodgkin's disease. PATIENTS AND METHODS Of 256 patients evaluated, 80 with a favorable prognosis according to a prognostic index designed by the Grupo Argentina de Tratamiento de Leucemia Aguda (GATLA) were randomized to three versus six cycles of CVPP without RT and 176 with intermediate risk to CVPP versus AOPE, both for six cycles with RT between the third and fourth cycles of 30 Gy to the involved areas at diagnosis. CVPP consisted of intravenous (I.V.) cyclophosphamide and vinblastine on days 1 and 8, and oral procarbazine and prednisone on days 1 to 14, every 28 days. AOPE consisted of I.V. doxorubicin and vincristine on day 1, oral prednisone on days 1 to 5, and I.V. etoposide on days 1 and 3, every 28 days. RESULTS Complete remission was obtained in 39 of 41 (95%) patients treated with three cycles of CVPP and 36 of 39 (92%) treated with six cycles in the favorable-risk group (difference not significant [NS]). In the intermediate-risk group, 89 of 92 (97%) treated with CVPP plus RT versus 75 of 84 (89%) treated with AOPE plus RT achieved a complete remission (P = .05). At 60 months, the event-free survival (EFS) and overall survival rates in the favorable-risk group were 80% and 91% for CVPP x 3 and 84% and 97% for CVPP x 6, respectively (P = NS). In the intermediate-risk group, 60-month EFS rate for CVPP plus RT was 85%, compared with 66% for AOPE plus RT (P = .009). The overall survival rate was 95% versus 87% respectively (P = .157). CONCLUSION Three cycles of CVPP without RT are equally effective as six cycles in the favorable-risk group. However, in the intermediate-group, CVPP plus RT is superior to AOPE plus RT, with significantly fewer events before and after induction (P = .009), without a difference in overall survival." @default.
• W1949806853 created "2016-06-24" @default.
• W1949806853 creator A5019745049 @default.
• W1949806853 creator A5025479875 @default.
• W1949806853 creator A5034186877 @default.
• W1949806853 creator A5040300777 @default.
• W1949806853 creator A5049185488 @default.
• W1949806853 creator A5049670577 @default.
• W1949806853 creator A5050998314 @default.
• W1949806853 creator A5051100371 @default.
• W1949806853 creator A5057219299 @default.
• W1949806853 creator A5063322723 @default.
• W1949806853 creator A5074350742 @default.
• W1949806853 creator A5075980362 @default.
• W1949806853 creator A5079543217 @default.
• W1949806853 creator A5080702645 @default.
• W1949806853 creator A5087177430 @default.
• W1949806853 creator A5090292061 @default.
• W1949806853 date "1997-07-01" @default.
• W1949806853 modified "2023-09-27" @default.
• W1949806853 title "Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease." @default.
• W1949806853 cites W1825210192 @default.
• W1949806853 cites W1825392456 @default.
• W1949806853 cites W1878173168 @default.
• W1949806853 cites W1880639950 @default.
• W1949806853 cites W1883598689 @default.
• W1949806853 cites W1917085797 @default.
• W1949806853 cites W1940006474 @default.
• W1949806853 cites W1955927002 @default.
• W1949806853 cites W1979300931 @default.
• W1949806853 cites W2006179649 @default.
• W1949806853 cites W2058128487 @default.
• W1949806853 cites W2065620512 @default.
• W1949806853 cites W2136776601 @default.
• W1949806853 cites W2165308914 @default.
• W1949806853 cites W2222626684 @default.
• W1949806853 cites W2260156623 @default.
• W1949806853 cites W2262902984 @default.
• W1949806853 cites W2324437943 @default.
• W1949806853 doi "https://doi.org/10.1200/jco.1997.15.7.2652" @default.
• W1949806853 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9215837" @default.
• W1949806853 hasPublicationYear "1997" @default.
• W1949806853 type Work @default.
• W1949806853 sameAs 1949806853 @default.
• W1949806853 citedByCount "29" @default.
• W1949806853 countsByYear W19498068532013 @default.
• W1949806853 countsByYear W19498068532014 @default.
• W1949806853 countsByYear W19498068532015 @default.
• W1949806853 countsByYear W19498068532016 @default.
• W1949806853 countsByYear W19498068532017 @default.
• W1949806853 countsByYear W19498068532020 @default.
• W1949806853 crossrefType "journal-article" @default.
• W1949806853 hasAuthorship W1949806853A5019745049 @default.
• W1949806853 hasAuthorship W1949806853A5025479875 @default.
• W1949806853 hasAuthorship W1949806853A5034186877 @default.
• W1949806853 hasAuthorship W1949806853A5040300777 @default.
• W1949806853 hasAuthorship W1949806853A5049185488 @default.
• W1949806853 hasAuthorship W1949806853A5049670577 @default.
• W1949806853 hasAuthorship W1949806853A5050998314 @default.
• W1949806853 hasAuthorship W1949806853A5051100371 @default.
• W1949806853 hasAuthorship W1949806853A5057219299 @default.
• W1949806853 hasAuthorship W1949806853A5063322723 @default.
• W1949806853 hasAuthorship W1949806853A5074350742 @default.
• W1949806853 hasAuthorship W1949806853A5075980362 @default.
• W1949806853 hasAuthorship W1949806853A5079543217 @default.
• W1949806853 hasAuthorship W1949806853A5080702645 @default.
• W1949806853 hasAuthorship W1949806853A5087177430 @default.
• W1949806853 hasAuthorship W1949806853A5090292061 @default.
• W1949806853 hasConcept C126322002 @default.
• W1949806853 hasConcept C141071460 @default.
• W1949806853 hasConcept C168563851 @default.
• W1949806853 hasConcept C2776694085 @default.
• W1949806853 hasConcept C2776755627 @default.
• W1949806853 hasConcept C2777132456 @default.
• W1949806853 hasConcept C2778119113 @default.
• W1949806853 hasConcept C2778720950 @default.
• W1949806853 hasConcept C2779112685 @default.
• W1949806853 hasConcept C2779429289 @default.
• W1949806853 hasConcept C509974204 @default.
• W1949806853 hasConcept C71924100 @default.
• W1949806853 hasConcept C90924648 @default.
• W1949806853 hasConceptScore W1949806853C126322002 @default.
• W1949806853 hasConceptScore W1949806853C141071460 @default.
• W1949806853 hasConceptScore W1949806853C168563851 @default.
• W1949806853 hasConceptScore W1949806853C2776694085 @default.
• W1949806853 hasConceptScore W1949806853C2776755627 @default.
• W1949806853 hasConceptScore W1949806853C2777132456 @default.
• W1949806853 hasConceptScore W1949806853C2778119113 @default.
• W1949806853 hasConceptScore W1949806853C2778720950 @default.
• W1949806853 hasConceptScore W1949806853C2779112685 @default.
• W1949806853 hasConceptScore W1949806853C2779429289 @default.
• W1949806853 hasConceptScore W1949806853C509974204 @default.
• W1949806853 hasConceptScore W1949806853C71924100 @default.
• W1949806853 hasConceptScore W1949806853C90924648 @default.
• W1949806853 hasIssue "7" @default.
• W1949806853 hasLocation W19498068531 @default.
• W1949806853 hasLocation W19498068532 @default.
• W1949806853 hasOpenAccess W1949806853 @default.

• next